 | Up a level |
Stahl, Mirjam; Roehmel, Jobst; Eichinger, Monika; Doellinger, Felix; Naehrlich, Lutz; Kopp, Matthias V; Dittrich, Anna-Maria; Sommerburg, Olaf; Ray, Partha; Maniktala, Anita; Xu, Tu; Conner, Sarah; Joshi, Aniket; Mascia, Molly; Wielpütz, Mark O; Mall, Marcus A (2024). Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2 Through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial. (In Press). Annals of the American Thoracic Society American Thoracic Society 10.1513/AnnalsATS.202402-201OC
Jakwerth, Constanze A; Weckmann, Markus; Illi, Sabina; Charles, Helen; Zissler, Ulrich M; Oelsner, Madlen; Guerth, Ferdinand; Omony, Jimmy; Nemani, Sai Sneha Priya; Grychtol, Ruth; Dittrich, Anna-Maria; Skevaki, Chrysanthi; Foth, Svenja; Weber, Stefanie; Alejandre Alcazar, Miguel A; van Koningsbruggen-Rietschel, Silke; Brock, Robert; Blau, Samira; Hansen, Gesine; Bahmer, Thomas; ... (2024). 17q21 Variants Disturb Mucosal Host Defense in Childhood Asthma. American journal of respiratory and critical care medicine, 209(8), pp. 947-959. American Lung Association 10.1164/rccm.202305-0934OC
Stahl, Mirjam; Roehmel, Jobst; Eichinger, Monika; Doellinger, Felix; Naehrlich, Lutz; Kopp, Matthias V; Dittrich, Anna-Maria; Lee, Christopher; Sommerburg, Olaf; Tian, Simon; Xu, Tu; Wu, Pan; Joshi, Aniket; Ray, Partha; Duncan, Margaret E; Wielpütz, Mark O; Mall, Marcus A (2023). Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo-controlled Clinical Trial. Annals of the American Thoracic Society, 20(8), pp. 1144-1155. American Thoracic Society 10.1513/AnnalsATS.202208-684OC
